FDA Needs Better Postmarket Data, Not More Postmarket Authority – Schultz
This article was originally published in The Gray Sheet
Executive Summary
FDA should establish a permanent network of hospitals to collect device postmarket data while lowering the evidence standard for market approval, Harvard Clinical Research Institute Chief Scientific Officer Richard Kuntz, MD, suggests
You may also be interested in...
CMS-Supported Clinical Data Collection Worth The Cost – Tunis
CMS will seek public comments early this year on criteria for deciding which national coverage policies should include data collection requirements
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.